Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Apr 11;67(3):301–310. doi: 10.1007/s10384-023-00985-w

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Japanese Ophthalmological Society 2023, corrected publication 2023Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.

PMC Copyright notice

Fig. 2 — Adjusted mean change in best-corrected visual acuity (BCVA; Early Treatment Diabetic Retinopathy Study [ETDRS] letters) from baseline up to week 48 in the a TENAYA Japan subgroup and b pooled global TENAYA/LUCERNE trials

^aAdjusted mean BCVA change from baseline averaged over weeks 40, 44, and 48

Results are based on mixed model for repeated measures (MMRM) analysis; missing data were implicitly imputed by MMRM. Error bars represent 95.03% confidence intervals (CIs) for the TENAYA Japan subgroup and 95% CIs for the pooled global TENAYA/LUCERNE trials. ITT intention-to-treat, Q8W every 8 weeks, Q16W every 16 weeks